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Background 
A phase II trial was performed to 
evaluate the efficacy and safety of 
gefitinib in patients with 
persistent/recurrent endometrial cancer. 
Methods  
Women with histologically confirmed 
persistent/recurrent endometrial cancer 
were treated with 500 mg oral gefitinib 
daily until progression or severe toxicity, 
with progression-free survival (PFS) at 
six months as the primary endpoint. 
Tumor expression of total epidermal 
growth factor receptor (EGFR), estrogen 
receptor (ER), progesterone receptor A 
(PRA) and B (PRB), Ki67, pEGFR and 
activated extracellular signal-regulated 
kinase (pERK) were examined pre- and 
post-treatment. EGFR was sequenced, 
and serum concentrations of soluble 
EGFR (sEGFR) at baseline also were 
examined. 
Results  
Of 29 patients enrolled, 26 were 
evaluable for efficacy and toxicity. Four 
patients experienced PFS≥6 months, 
and one had a complete response which 
was not associated with an EGFR 
mutation. The concentration of sEGFR 
in pretreatment serum was positively 
correlated with overall survival (OS), but 
not with responsiveness to gefitinib in 
this small patient cohort. Expression of 
tumor biomarkers was not associated 
with PFS or OS. Co-expression of 
ERwith PRA in primary and recurrent 
tumors, and pEGFRwith pERK in 
primary tumors was observed. 
Conclusions 
This treatment regimen was tolerable 
but lacked sufficient efficacy to warrant 
further evaluation in this setting. The 
possible association between serum 
sEGFR concentrations and OS, and 
temporal changes in expression of 
pEGFR and pERK and the documented 
CR of one patient are interesting and 
warrant additional investigation. 
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